CTRI/2009/091/000566已完成2 期
Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Patients with Diffuse Large B-Cell Lymphoma following Autologous Stem Cell Transplantation
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- CureTech Ltd
- 入组人数
- 68
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patient's age is 18 years or older, both genders.
- •2.Confirmed Diffuse Large B-cell Lymphoma, transformed follicular lymphoma, diffuse mixed cell lymphoma or primary mediastinal large cell lymphoma with B-cell lineage.
- •3.The lymphoma is chemosensitive.
- •4.The lymphoma did not progress since pre-transplant chemotherapy.
- •5.ECOG performance status 0-1.
排除标准
- •1.Serious other illness.
- •2.Active autoimmune disease.
- •3.Type 1 diabetes.
- •4.Known immune deficiency.
- •5.Clinical evidence of primary or secondary brain or spinal cord involvement by lymphoma.
- •6.Active bacterial, fungal, or viral infection.
- •7.Positive HIV, Hepatitis B surface antigen plus viremia, or Hepatitis C antibody plus viremia.
- •8.Pregnant or nursing (positive pregnancy test).
- •9.Other concurrent clinical study or investigational therapy.
研究者
相似试验
已完成
不适用
Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Patients With Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantatio-C851 B-cell lymphoma, unspecifiedB-cell lymphoma, unspecifiedC851PER-097-09CureTech Ltd,
未知
2 期
Phase 2 Study of MR13A9.JPRN-jRCT2080223210Maruishi Pharmaceutical Co., Ltd.100
已完成
不适用
Phase II study evaluating safety and efficacy of maintenance therapy with bortezomib, lenalidomide and dexamethasone for multiple myelomaMultiple MyelomaJPRN-UMIN000008236Fourth Department of Internal Medicine, Sapporo Medical University Hospital30
进行中（未招募）
不适用
A phase 2a Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks with AuraMIgraine with auraEUCTR2009-010721-39-DKPeer Tfelt-Hansen
已完成
2 期
A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers: REZOLVEACTRN12611000801910niversity of Sydney24